ResMed Shares Tumble 6% on Disappointing 2027 Revenue Guidance

Key Facts

Amid rising concerns over sustainable growth in the medtech sector, ResMed faced intense selling pressure following disappointing financial updates. The company's shares tumbled 6% after forecasting fiscal 2027 revenue below Wall Street expectations, despite reporting a quarterly profit beat. According to reports, this downward revision in long-term guidance was primarily driven by the suspension of ventilator sales and ongoing operational cost pressures impacting profit margins.

These price movements reflect investor sensitivity toward long-term outlooks in the healthcare equipment industry, where future sales concerns outweighed current financial performance. Per market data, the company's forward-looking sentiment was dampened by persistent cost pressures that may limit expansion capabilities given the logistical challenges associated with halting key product lines like ventilators.

Regarding market performance, RMD closed at $223.24 as of August 6, 2026, with the session seeing a range between $222.2 and $226.12. With no direct medical sector catalysts in the immediate calendar, traders are monitoring current support levels while looking toward broader economic indicators such as the U.S. JOLTs Job Openings on August 4, 2026, to gauge general market sentiment.